Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Antiphospholipid Syndrome (APS)
NCT07172022Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of crovalimab in antiphospholipid syndrome (APS), sponsored by Roche. Planned start Mar 2026; status: withdrawn.
02
Drugs
crovalimab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT07172022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172022.